LightWave Acquisition Corp. Class A Ordinary Shares
LWAC
LightWave Acquisition Corp is a blank check company.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$10.41 – $10.41
Volume11
Market cap$313M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for LWAC.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for LWAC.
Recent news
Company coverage with links to the original publishers.
Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved.
eFFECTOR Therapeutics is focused on selective translation regulation inhibitors to treat cancer. The SPAC merger valued the company at $419 million, including a $60 million PIPE with an investment from Pfizer Inc's (NYSE: PFE) venture capital arm Pfizer Ventures.
Related Link: Exclusive: Accelerate CEO On SPAC Arbitrage, Why You Can't Always Bet On SPAC Sponsor
Why The Stock Is Soaring: Locust Walk Acquisition raised $175 million in its IPO, selling 17.5 ...
Clinical-stage biopharmaceutical company eFFECTOR Therapeutics is set to go public via the special purpose acquisition company Locust Walk Acquisition Corp (NASDAQ: LWAC) with an enterprise value of $419 million.
Steve Worland, the president and CEO of eFFECTOR, and Chris Ehrlich, CEO of Locust Walk Acquisition Corp., appeared on Benzinga's YouTube show "SPACs Attack" for an exclusive interview Wednesday.
eFFECTOR Programs: eFFECTOR focuses on using a new class of oncology drugs known as selective translation regulation inhibitors to treat cancer.
eFFECTOR has a global partnership with Pfizer Inc (NYSE: PFE) for the development of inhibitors of eIF4E, which is the company's earliest stage program, Worland told Benzinga.
Tomivosertib, which targets non-small cell lung cancer, is in late-stage Phase 2 trials and is the furthest along of eFFECTOR's programs, he said, adding ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.